Innoviva Other Non-Current Liabilities 2010-2024 | INVA
Innoviva other non-current liabilities from 2010 to 2024. Other non-current liabilities can be defined as field containing the sum of all non-current liabilities that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
Innoviva Annual Other Non-Current Liabilities
(Millions of US $) |
| 2023 |
$84 |
| 2022 |
$81 |
| 2021 |
$ |
| 2020 |
$0 |
| 2019 |
$0 |
| 2018 |
$1 |
| 2017 |
$1 |
| 2016 |
$1 |
| 2015 |
$2 |
| 2014 |
$2 |
| 2013 |
$ |
| 2012 |
$ |
| 2011 |
$ |
| 2010 |
$ |
| 2009 |
$0 |
Innoviva Quarterly Other Non-Current Liabilities
(Millions of US $) |
| 2024-06-30 |
$84 |
| 2024-03-31 |
$83 |
| 2023-12-31 |
$84 |
| 2023-09-30 |
$79 |
| 2023-06-30 |
$79 |
| 2023-03-31 |
$80 |
| 2022-12-31 |
$81 |
| 2022-09-30 |
$78 |
| 2022-06-30 |
|
| 2022-03-31 |
|
| 2021-12-31 |
|
| 2021-09-30 |
$0 |
| 2021-06-30 |
$0 |
| 2021-03-31 |
$0 |
| 2020-12-31 |
$0 |
| 2020-09-30 |
$0 |
| 2020-06-30 |
$0 |
| 2020-03-31 |
$0 |
| 2019-12-31 |
$0 |
| 2019-09-30 |
$0 |
| 2019-06-30 |
$0 |
| 2019-03-31 |
$0 |
| 2018-12-31 |
$1 |
| 2018-09-30 |
$1 |
| 2018-06-30 |
$1 |
| 2018-03-31 |
$1 |
| 2017-12-31 |
$1 |
| 2017-09-30 |
$1 |
| 2017-06-30 |
$1 |
| 2017-03-31 |
$1 |
| 2016-12-31 |
$1 |
| 2016-09-30 |
$2 |
| 2016-06-30 |
$2 |
| 2016-03-31 |
$2 |
| 2015-12-31 |
$2 |
| 2015-09-30 |
$2 |
| 2015-06-30 |
$2 |
| 2015-03-31 |
$2 |
| 2014-12-31 |
$2 |
| 2014-09-30 |
$2 |
| 2014-06-30 |
$1 |
| 2014-03-31 |
|
| 2013-12-31 |
|
| 2013-09-30 |
|
| 2013-06-30 |
|
| 2013-03-31 |
|
| 2012-12-31 |
|
| 2012-09-30 |
|
| 2012-06-30 |
|
| 2012-03-31 |
|
| 2011-12-31 |
|
| 2011-09-30 |
|
| 2011-06-30 |
|
| 2011-03-31 |
|
| 2010-12-31 |
|
| 2010-09-30 |
|
| 2010-06-30 |
|
| 2010-03-31 |
$0 |
| 2009-12-31 |
$0 |
| 2009-09-30 |
$0 |
| 2009-06-30 |
$1 |
| 2009-03-31 |
$1 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$1.222B |
$0.310B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
